Fig. 1.
Subject flow diagram throughout the 12-month romosozumab treatment period. Subjects receiving selective estrogen receptor modulators or vitamin D3 as previous treatments were excluded from the study.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.